Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 3:03 AM
Ignite Modification Date:
2025-12-25 @ 3:03 AM
NCT ID:
NCT05535933
Brief Summary:
Phase II Study: To evaluate the safety and preliminary efficacy of HMPL-523 in adult patients with wAIHA
Phase III Studies: Confirmation of Efficacy safety and of HMPL-523 in Adult Patients With wAIHA
Detailed Description:
Phase II Study: the proportion of patients with overall Hb response by Week 24
Phase III study: the proportion of patients who achieve a durable response by Week 24
Study:
NCT05535933
Study Brief:
Protocol Section:
NCT05535933